• Create serum and body fluid proteomic profiling by surface-enhanced laser desorption and ionization with time-of-flight detection (SELDI-TOF) and artificial intelligence at baseline, 1 mo., and then every 3 mo. [ Designated as safety issue: No ]
  
• Sensitivity and specificity of the serum proteomic signature profiles measured by SELDI-TOF and artificial intelligence at baseline, 1 month, and then every 3 months [ Designated as safety issue: No ]
  
• Sensitivity & specificity of proteomic signature profiles of serum, body fluid and tumor biopsy compared with CA-125 serum tumor marker profiles by SELDI-TOF & artificial intelligence and serum CA-125 at baseline, 1 mo. and then every 3 mo. [ Designated as safety issue: No ]
  

OBJECTIVES:

• Create serum and body fluid protein profiles of patients with stage III or IV primary peritoneal, fallopian tube, or ovarian epithelial cancer, or stage IIC ovarian clear cell cystadenocarcinoma in first remission through relapse.
• Analyze expressed protein profiles to try to identify a pattern or changes in patterns associated with relapse in this patient population.
• Compare expressed protein profiles in blood and body fluids at relapse with expressed protein patterns in tumor relapse specimen of these patients.
• Determine the associative/predictive value of serum lysophosphatidic acid measurements for ovarian cancer relapse.

OUTLINE: Patients undergo history, physical examination with pelvic examination, laboratory evaluation, and noninvasive imaging at baseline, 1 month, 3 months, and every 3 months thereafter. Samples are analyzed by surface enhanced laser desorption ionization spectrometry to identify protein profiles. Samples are also analyzed for lysophosphatidic acid. Patient evaluation continues until biopsy proven relapse.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.